We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New One Minute Coronavirus Test Offers More than 90% Accuracy at Dramatically Lower Price

By LabMedica International staff writers
Posted on 14 May 2020
Israeli researchers have developed and are now validating a test that identifies carriers of the COVID-19 virus in less than a minute with greater than 90% accuracy and at a dramatically lower price than any other method available.

The test, developed by Ben-Gurion University of the Negev {(BGU) Beer-Sheva, Israel}, uses a chip with a dense array of metamaterial sensors that was designed specifically for this purpose. More...
Particles from a simple breath test or throat and nose swabs, such as those already currently used for other tests, are placed on the chip. The system then analyzes the biological sample and provides an accurate positive/negative result within a minute via a cloud-connected system. The point-of-care device automatically backs up the results into a database that can be shared by authorities, making it easier than ever to track the course of the virus, as well as triage and treat patients.

The new method is based on the change in the resonance in the THz spectral range imposed by the coronavirus through a THz spectroscopy performed on the device. This spectral range has been employed in recent decades for the fast detection and identification of biological samples. Being electro-optical in nature, rather than biochemical, the test is not sensitive to environmental factors that can affect results of current testing methods.

Each test kit would cost between USD 50-100 to produce, which is far less than the current coronavirus test kits based on amplifying and identifying the viral RNA sequences, and therefore depend on costly reagents and biochemical reactions. Additionally, these PCR-based kits take hours, and in many cases days, to yield results and require logistically complicated shipping and handling of sensitive and infectious biological samples. In clinical trials, the test has demonstrated a better than 90% success rate as compared to Polymerase Chain Reaction (PCR) tests. Ongoing trials will now seek to determine if the test can identify the specific stage of COVID-19 infection as well as its presence.

"Right from the beginning of the trials, we received statistically significant results in line with our simulations and PCR tests," said Prof. Sarusi, deputy head for research at the School of Electrical and Computer Engineering and a faculty member of the Electro-Optical Engineering Unit at BGU. "We are continuing clinical trials and will compare samples from COVID-19 patients with samples from patients with other diseases to see if we can identify the different stages of the COVID-19 infection."

Related Links:
Ben-Gurion University of the Negev (BGU)


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.